B-Cell immunotherapy
Showing 1 - 25 of >10,000
Pediatric and Young Adult B-Cell Malignancies After Commercially
Not yet recruiting
- Lymphoid Leukemia
- Questionnaire for patients receiving therapy
-
Palo Alto, CaliforniaStanford University
May 9, 2023
Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- BTK inhibitor
- PD-1 inhibitor
-
Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, NSCLC Stage IV Trial in Australia, United States (IMU-201
Recruiting
- Non Small Cell Lung Cancer
- +5 more
- IMU-201 (administered as PD1-Vaxx)
-
Phoenix, Arizona
- +5 more
Jan 19, 2022
B-cell Acute Lymphoblastic Leukemia Trial in Sanhe (GC007F)
Completed
- B-cell Acute Lymphoblastic Leukemia
- GC007F
-
Sanhe, Hebei, ChinaHebei Yanda Ludaopei Hospital
Apr 21, 2022
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (Chemotherapy, Pembrolizumab, Ramucirumab)
Not yet recruiting
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Chemotherapy
- +2 more
- (no location specified)
Jan 9, 2023
CNS Tumor, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma Trial in Seattle (SCRI-CARB7H3(s); B7H3-specific chimeric
Recruiting
- Central Nervous System Tumor
- +10 more
- SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel
-
Seattle, WashingtonSeattle Children's Hospital
Dec 14, 2022
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Recurrent CNS Tumor, Adult Trial in Seattle (SC-CAR4BRAIN)
Not yet recruiting
- Diffuse Intrinsic Pontine Glioma
- +4 more
- SC-CAR4BRAIN
-
Seattle, WashingtonSeattle Children's Hospital
Mar 3, 2023
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +20 more
- Chimeric Antigen Receptor T-Cell Therapy
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 11, 2022
Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,
Not yet recruiting
- Kidney Transplant
- +2 more
- Cyclophosphamide
- +3 more
-
Boston, Massachusetts
- +2 more
Sep 20, 2023
Recurrent DLBCL, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory DLBCL Trial in United States (drug, other, biological)
Active, not recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +5 more
- Atezolizumab
- +9 more
-
Duarte, California
- +3 more
Nov 17, 2022
NSCLC, Progression of NSCLC, NSCLC Recurrent Trial in Saint Louis, Cincinnati (Docetaxel, Tergenpumatucel-L, Indoximod)
Terminated
- Non-small Cell Lung Cancer
- +2 more
- Docetaxel
- +2 more
-
Saint Louis, Missouri
- +1 more
Apr 4, 2022
NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)
Recruiting
- Non-Small Cell Lung Cancer
- +5 more
- Toripalimab
- +3 more
-
Guanzhou, Guangdong, ChinaGuangdong Lung Cancer Institute, Guangdong Provincial People's H
Apr 4, 2023
Advanced or Metastatic NSCLC Trial in Worldwide (Datopotamab deruxtecan, Durvalumab, Carboplatin)
Recruiting
- Advanced or Metastatic NSCLC
- Datopotamab deruxtecan
- +4 more
-
Santa Ana, California
- +15 more
Dec 13, 2022
Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL) Trial in
Recruiting
- Diffuse Large-Cell Lymphoma
- +3 more
- Pneumococcal conjugate vaccine (PCV13)
- CD19 targeted CAR T Cell Therapy
-
Tampa, FloridaMoffitt Cancer Center
May 31, 2022
Myasthenia Gravis, Generalized Trial in Roma (Rituximab, Placebo)
Recruiting
- Myasthenia Gravis, Generalized
- Rituximab
- Placebo
-
Roma, ItalyPoliclinico A. Gemelli IRCCS
May 25, 2023
Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma, DLBCL Transformed From Follicular Lymphoma Trial run by the
Completed
- Primary Mediastinal B-cell Lymphoma
- +3 more
- Fludarabine
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 29, 2021
Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small
Recruiting
- Platinum-Resistant Lung Small Cell Carcinoma
- +3 more
- Durvalumab
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 5, 2023
Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,
Active, not recruiting
- Adult Grade III Lymphomatoid Granulomatosis
- +23 more
- autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 4, 2023
Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 Trial in Rochester (Durvalumab, Radiation Therapy)
Not yet recruiting
- Lung Non-Small Cell Carcinoma
- Stage III Lung Cancer AJCC v8
- Durvalumab
- Radiation Therapy
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
Advanced Renal Cell Carcinoma Trial in United States (CMN-001, Nivolumab+Ipilimumab, Lenvatinib+Everolimus)
Recruiting
- Advanced Renal Cell Carcinoma
- CMN-001
- +2 more
-
Tampa, Florida
- +6 more
Feb 10, 2022
Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic Trial in Canada, United States (SLC-391, Pembrolizumab)
Not yet recruiting
- Lung Cancer, Nonsmall Cell
- +2 more
- SLC-391
- Pembrolizumab
-
Indianapolis, Indiana
- +8 more
May 5, 2023
Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma AJCC v7 Trial in Seattle (drug, other, biological, radiation)
Terminated
- Merkel Cell Polyomavirus Infection
- Stage IV Merkel Cell Carcinoma AJCC v7
- Avelumab
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Feb 25, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 3, 2022